Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma >3–<5 cm

Reference

• Chinn SB, Lee FT Jr, Kennedy GD, et al. Effect of vascular occlusion on radiofrequency ablation of the liver: results in a porcine model. Am J Roentgenol. 2001;176:789–795.
   PubMed Web of Science ®Google Scholar
• Goldberg SN, Kamel IR, Kruskal JB, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. Am J Roentgenol. 2002;179:93–101.
   PubMed Web of Science ®Google Scholar
• Mostafa EM, Ganguli S, Faintuch S, et al. Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors. J Vasc Interv Radiol. 2008;19:1740–1748.
   PubMed Web of Science ®Google Scholar
• Smolock AR, Cristescu MM, Hinshaw A, et al. Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone. Abdom Radiol (NY). 2018;43:2497–2504.
   PubMed Web of Science ®Google Scholar
• Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Curr Probl Diagn Radiol. 2009;38:135–143.
   PubMedGoogle Scholar
• European Association for the Study of the Liver. Corrigendum to "EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma" [J Hepatol 69 (2018) 182-236]. J Hepatol. 2019;70:817.
   PubMed Web of Science ®Google Scholar
• Brace CL, Laeseke PF, Sampson LA, et al. Microwave ablation with multiple simultaneously powered small-gauge triaxial antennas: results from an in vivo swine liver model. Radiology. 2007;244:151–156.
   PubMed Web of Science ®Google Scholar
• Liang P, Dong B, Yu X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology. 2005;235:299–307.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Int J Hyperthermia. 2016;32:339–344.
   PubMed Web of Science ®Google Scholar
• Yang WZ, Jiang N, Huang N, et al. Combined therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation for small hepatocellular carcinoma. WJG. 2009;15:748.
   PubMed Web of Science ®Google Scholar
• Seki T, Tamai T, Nakagawa T, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer. 2000;89:1245–1251.
   PubMed Web of Science ®Google Scholar
• Xu LF, Sun HL, Chen YT, et al. Large primary hepatocellular carcinoma: Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization‐percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28:456–463.
   PubMed Web of Science ®Google Scholar
• Zheng L, Li HL, Guo CY, et al. Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with large solitary or multinodular hepatocellular carcinomas. Korean J Radiol. 2018;19:237–246.
   PubMed Web of Science ®Google Scholar
• Khalilzadeh O, Baerlocher MO, Shyn PB, et al. Proposal of a new adverse event classification by the Society of Interventional Radiology Standards of Practice Committee. J Vasc Interv Radiol. 2017;28:1432–1437.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
   PubMed Web of Science ®Google Scholar
• de Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol. 2012;56:S75–S87.
   PubMed Web of Science ®Google Scholar
• Si ZM, Wang GZ, Qian S, et al. Combination therapies in the management of large (≥ 5 cm) hepatocellular carcinoma: microwave ablation immediately followed by transarterial chemoembolization. J Vasc Interv Radiol. 2016;27:1577–1583.
   PubMed Web of Science ®Google Scholar
• Yi Y, Zhang Y, Wei Q, et al. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. Chin J Cancer Res. 2014;26:112–118.
   PubMed Web of Science ®Google Scholar
• Chen QF, Jia ZY, Yang ZQ, Fan WL, et al. Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization–microwave ablation therapy for hepatocellular carcinoma tumors≤ 5 cm: a propensity analysis at a single center. Cardiovasc Intervent Radiol. 2017;40:1748–1755.
   PubMed Web of Science ®Google Scholar
• Yuan W, Yang MJ, Xu J, et al. Radiofrequency ablation combined with transarterial chemoembolization for specially located small hepatocellular carcinoma. Technol Cancer Res Treat. 2018;17:1533033818788529.
   Web of Science ®Google Scholar
• Abdelaziz AO, Abdelmaksoud AH, Nabeel MM, et al. Transarterial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma. Asian Pac J Cancer Prev. 2017;18:189–194.
   PubMedGoogle Scholar
• Zhang R, Shen L, Zhao L, et al. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol. 2018;24:219–224.
   PubMed Web of Science ®Google Scholar
• Poggi G, Montagna B, Di CP, et al. Microwave ablation of hepatocellular carcinoma using a new percutaneous device: preliminary results. Anticancer Res . 2013;33:1221–1227.
   PubMed Web of Science ®Google Scholar
• Li W, Man W, Guo H, et al. Clinical study of transcatheter arterial chemoembolization combined with microwave ablation in the treatment of advanced hepatocellular carcinoma. J Can Res Ther. 2016;12:217.
   PubMed Web of Science ®Google Scholar
• Ginsburg M, Zivin SP, Wroblewski K, et al. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation. J Vasc Interv Radiol. 2015;26:330–341.
   PubMed Web of Science ®Google Scholar
• Yin X, Zhang L, Wang YH, et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. BMC Cancer. 2014;14:849.
   PubMed Web of Science ®Google Scholar
• Liu C, Liang P, Liu F, et al. MWA combined with TACE as a combined therapy for unresectable large-sized hepotocellular carcinoma. Int J Hyperthermia. 2011;27:654–662.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiao D, Han X, et al. Transcatheter arterial chemoembolization combined with simultaneous DynaCT-guided microwave ablation in the treatment of small hepatocellular carcinoma. Cancer Imaging. 2020;20:13
   PubMed Web of Science ®Google Scholar
• Hu H, Chen GF, Yuan W, et al. Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis. Int J Hyperthermia. 2018;34:1351–1358.
   PubMed Web of Science ®Google Scholar
• Kohles N, Nagel D, Jüngst D, et al. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33:33–40.
   PubMed Web of Science ®Google Scholar
• Tsai MC, Wang JH, Hung CH, et al. Favorable alpha-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation . J Gastroenterol Hepatol. 2010;25:605–612.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao Y, Jia J, et al. The prognostic value of alpha-fetoprotein response for advanced-stage hepatocellular carcinoma treated with sorafenib combined with transarterial chemoembolization. Sci Rep. 2016;6:19851–19859.
   PubMed Web of Science ®Google Scholar